Sterling Investment Advisors (Pennsylvania)’s United Therapeutics UTHR Stock Holding History

Sterling Investment Advisors (Pennsylvania)’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,400	Closed	-$191K	–	442
2019 Q3	$191K	Sell	2,400 -725	-23%	-$58.4K	0.1%	111
2019 Q2	$244K	Sell	3,125 -1,950	-38%	-$182K	0.12%	102
2019 Q1	$596K	Hold	5,075	–	–	0.3%	80
2018 Q4	$552K	Sell	5,075 -875	-15%	-$101K	0.32%	77
2018 Q3	$761K	Hold	5,950	–	–	0.4%	65
2018 Q2	$673K	Buy	5,950 +250	+4%	+$27.5K	0.4%	68
2018 Q1	$640K	Buy	5,700 +300	+6%	+$38.1K	0.39%	67
2017 Q4	$799K	Buy	5,400 +1,250	+30%	+$159K	0.5%	63
2017 Q3	$486K	Hold	4,150	–	–	0.32%	75
2017 Q2	$538K	Buy	4,150 +2,200	+113%	+$274K	0.36%	73
2017 Q1	$264K	Hold	1,950	–	–	0.19%	87
2016 Q4	$280K	Buy	+1,950	New	+$249K	0.22%	79

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Sterling Investment Advisors (Pennsylvania)'s UTHR Position: Q4 2019 in Review

Sterling Investment Advisors (Pennsylvania) sold out of United Therapeutics (UTHR) in Q4 2019, closing a stake of 2,400 shares — an estimated $191K sold.

Sterling Investment Advisors (Pennsylvania) first reported a position in UTHR in Q4 2016 and held it in 12 quarters. The position peaked at $799K in Q4 2017. 320 funds tracked by Wall St. Rank hold UTHR as of Q4 2019.

Sterling Investment Advisors (Pennsylvania) reported no remaining United Therapeutics position as of Q4 2019 after selling out during the quarter.
Sterling Investment Advisors (Pennsylvania) sold 2,400 United Therapeutics shares in Q4 2019, an estimated $191K.
Sterling Investment Advisors (Pennsylvania) first reported a position in United Therapeutics in Q4 2016 and held it in 12 quarters.
Sterling Investment Advisors (Pennsylvania)'s United Therapeutics position peaked at $799K in Q4 2017.
320 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2019.

Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q4 2019, filed 10 Feb 2020.